Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 421 results for stroke

  1. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  2. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  3. Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

    NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .

  4. Multimorbidity (QS153)

    This quality standard covers clinical assessment, prioritising and managing healthcare for adults aged 18 years and over with 2 or more long-term health conditions (multimorbidity). At least 1 of these conditions must be a physical health condition. It describes high-quality care in priority areas for improvement.

  5. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

  6. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  7. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  8. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

  9. Type 1 diabetes in adults (QS208)

    This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.

  10. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

  11. VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)

    Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.

  12. VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  13. Insertion of a magnetic bead band for faecal incontinence (HTG336)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

  14. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  15. There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.

    guidance details Comes from guidance Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial...